Arterial StiffnessArterial Stiffness
有病率: Universal with aging; 20-30% of adults >60 have PWV >10 m/s
Evidence-Ranked Ingredients
| 成分 | グレード | 研究数 | 効果の方向 | |
|---|---|---|---|---|
| Vitamin K2 | B | 5 | Positive | 詳細を見る → |
| NMN (Nicotinamide Mononucleotide) | C | 2 | Positive | 詳細を見る → |
About
Elastin is deposited in the arterial wall early in life and is replaced only marginally thereafter. Over decades of pulsation the elastic lamellae fatigue and fracture, collagen accumulates in their place, and cross-links form between collagen molecules through non-enzymatic glycation. The aorta consequently becomes stiffer with age in every population studied, and between 20 and 30 percent of adults over 60 have a carotid-femoral pulse wave velocity above 10 m/s, the conventional threshold for abnormal stiffening.
The haemodynamic consequence follows from the physics. A compliant aorta absorbs part of each stroke volume during systole and releases it during diastole, smoothing flow and reducing the load on the ventricle. A stiff aorta cannot store that volume, so systolic pressure rises while diastolic pressure falls, widening the pulse pressure. The reflected pressure wave returning from the periphery also travels faster and arrives during systole rather than diastole, adding to peak load. This is the mechanism behind isolated systolic hypertension in older adults, and it explains why the condition is asymptomatic while still increasing cardiac workload measurably.
Ageing is the primary driver. Hypertension accelerates the same process through increased wall stress. Diabetes contributes through advanced glycation end-products, which cross-link collagen directly and are the clearest molecular link between glycaemic exposure and vascular ageing. Chronic kidney disease adds medial calcification, a distinct mechanism of stiffening rather than a variant of the elastin story. Dyslipidaemia, smoking and the oestrogen decline of menopause complete the recognised list.
Two ingredients are graded against this endpoint in the collection, on 7 studies and 1,300 participants between them. Vitamin K2 holds Grade B on 5 studies and 1,200 participants. Its rationale is specific and biologically well defined: matrix Gla protein, an inhibitor of vascular calcification, requires vitamin K-dependent gamma-carboxylation to function, and the uncarboxylated form is measurable in circulation as an index of vascular vitamin K status. This makes K2 unusual among ingredients studied here, since it addresses one identified mechanism of stiffening rather than a general antioxidant or vasodilatory hypothesis. It is also the reason the interaction with vitamin K antagonist anticoagulants is not incidental but pharmacologically direct.
NMN holds Grade C on 2 studies and 100 participants. Its inclusion follows from work on NAD availability and sirtuin signalling in vascular ageing rather than from a body of clinical trial evidence at this endpoint, and two studies with 100 participants cannot support more than a preliminary reading.
No research paper is currently linked to this condition in the collection, so the graded entries above stand on the study counts recorded for them rather than on citable primary sources here. Pulse wave velocity remains the measured quantity, and it responds to blood pressure control, glycaemic control and physical activity on evidence bases considerably larger than either ingredient's.
Common Symptoms
Risk Factors
- Aging (primary driver)
- Hypertension
- Diabetes
- Chronic kidney disease
- Dyslipidemia
- Smoking
- Menopause (estrogen decline)
Frequently Asked Questions
What supplements may help with Arterial Stiffness?
How is the evidence for Arterial Stiffness supplements graded?
How many studies on Arterial Stiffness supplements have been reviewed?
What are common symptoms of Arterial Stiffness?
Related Conditions
共通の研究済み成分を持つ症状
FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。